课题基金 / 基金详情

NSF/FDA SIR: 3D Engineered Tissue Models for In Vitro Safety Testing of Nanoparticles

NSF/FDA SIR: 3D Engineered Tissue Models for In Vitro Safety Testing of Nanoparticles
NSF/FDA SIR:用于纳米颗粒体外安全测试的 3D 工程组织模型
批准号:
1237549
负责人:
Jan Stegemann
金额:
$10.53万
依托单位国家:
美国
项目类别:
Standard Grant
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-07-01 至 2014-06-30
关键词:

项目摘要

项目成果

Jan Stegemann的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Abstract#1237549StegemannThe goal of this 1-year Scholar-in-Residence project is to develop enhanced in vitro testing methods to rigorously evaluate the safety of nanoparticles, which are increasingly being used as components of medical devices. In response to this emerging need, the U.S. Food and Drug Administration (FDA) has initiated efforts to characterize the biological effects of nanoparticles. In particular, the Office of Science and Engineering Laboratories (OSEL) in the Center for Devices and Radiological Health (CDRH) has a strong interest in nanotechnology and evaluating nanotoxicity. The PI's lab at the University of Michigan (UMich) has a longstanding interest in characterizing cell function in well defined and consistent engineered tissues composed of cells embedded directly in a 3D protein matrix, and also has been working on cell-nanoparticle interactions in these systems. Such engineered tissues mimic important aspects of the 3D environment of native tissues, and therefore have the potential to provide information on nanoparticle biocompatibility that is not available from conventional 2D cultures or animal studies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
NSF/FDA SIR: Three-Dimensional In Vitro Modeling of Interactions Between Orthopedic Wear Particles, Biofilm, and Macrophages
NSF/FDA SIR: Impact of Mechanotransduction in Polymer Microparticle-Induced Macrophage Inflammation and Osteolysis
NSF/FDA SIR: 3D Cell Culture Models as Regulatory Tools for Screening Macrophage Responses to Polymer Wear Debris.
I-Corps: Matrix-Enhanced Delivery of Cell Therapy
国内基金
海外基金
FDA上市药物库筛选鉴定靶向治疗ARID1A缺陷型结直肠癌的合成致死效应及分子机制研究
  • 批准号:
    82373165
  • 项目类别:
    面上项目
  • 资助金额:
    49万元
  • 批准年份:
    2023
  • 负责人:
    李爱民
  • 依托单位:
多维互质结构FDA雷达稀疏空时距自适应处理研究
  • 批准号:
    61771317
  • 项目类别:
    面上项目
  • 资助金额:
    62.0万元
  • 批准年份:
    2017
  • 负责人:
    阳召成
  • 依托单位:
基于FDA标记畸胎瘤细胞联合人胎盘屏障体外模型建立中药胚胎毒性评价体系的研究
  • 批准号:
    81573740
  • 项目类别:
    面上项目
  • 资助金额:
    63.0万元
  • 批准年份:
    2015
  • 负责人:
    宋殿荣
  • 依托单位: